Efficacy of tacrolimus in the treatment of children with focal segmental glomerulosclerosis
Tóm tắt
Focal segmental glomerulosclerosis (FSGS) is the most common glomerular condition leading to end-stage renal disease (ESRD) and the third most common cause of ESRD in pediatric patients. This is a retrospective study consisting of 22 pediatric patients with FSGS and heavy proteinuria. After demonstrating steroids resistance, the patients were treated with tacrolimus, targeting a trough level 5–8 ng/mL. The primary outcome is the induction of remission with tacrolimus. Thirteen patients (59%) achieved remission (complete in 31.8% and partial in 27.2%) and 12 patients showed stable or improved renal function over an average follow-up of 2.9 years (range: 0.5–7 years). There was no significant difference in response rate between African American and Caucasian patients. None of the patients had significant side-effect to tacrolimus and none of the repeat biopsies showed an increase in interstitial fibrosis compared to baseline. The best renal outcome was for patients who achieved complete remission. Partially responsive patients had improved renal function compared with resistant patients. Tacrolimus is a viable option in the treatment of children with idiopathic steroid resistant FSGS.
Tài liệu tham khảo
Hogg R, Silva F, Berry P, Hawkins E, Hill L, Sanjad S, et al. Focal segmental glomerulosclerosis in children with idiopathic nephrotic syndrome. A report of the southwest pediatric nephrology study group. Kidney Int 1985;27:442–449.
D’Agati VD, Kaskel FJ, Falk RJ. Focal segmental glomerulosclerosis. New Engl J Med 2011;365:2398–2411.
Collins A, Foley R, Chavers B, Gilbertson D, Herzog C, Johansen K, et al. National Institutes of Health. Renal Data System. USRDS 2010 annual data report: atlas of chronic kidney disease and end stage renal disease in the United States. Bethesda, MD. National Institute of Diabetes and Digestive and Kidney Diseases, 2010: 1–22.
Smith JM, Stablein DM, Munoz R, Hebert D, McDonald RA. Contributions to the transplant registry: the 2006 report of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Pediatr Transplant 2007;11:366–373.
Paik KH, Lee BH, Cho HY, Kang HG, Ha IS, Cheong HI, et al. Primary focal segmental glomerulosclerosis in children: clinical course and prognosis. Pediatr Nephrol 2007;22:389–395.
Schonenberger E, Ehrich JH, Haller H, Schiffer M. The podocyte as a direct target of immunosuppressive agents. Nephrol Dial Transplant 2011;26:18–24.
Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. Am J Kidney Dis 2009;53:760–769.
Bhimma R, Adhikari M, Asharam K, Connolly C. Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol 2006;26:544–551.
Butani L, Ramsamooj R. Experience with tacrolimus in children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 2009;24:1517–1523.
Gipson DS, Trachtman H, Kaskel FJ, Greene TH, Radeva MK, Gassman JJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011;80:868–878.
Gulati S, Prasad N, Sharma RK, Kumar A, Gupta A, Baburaj VP. Tacrolimus: a new therapy for steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2008;23:910–913.
Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomised trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999;56:2220–2226.
Tucker JK. Focal segmental glomerulosclerosis in African Americans. Am J Med Sci 2002;323:90–93.
Roberti I, Vyas S. Long-term outcome of children with steroidresistant nephrotic syndrome treated with tacrolimus. Pediatr Nephrol 2010;25:1117–1124.
Fujinaga S, Kaneko K, Muto T, Ohtomo Y, Murakami H, Yamashiro Y. Independent risk factors for chronic cyclosporine induced nephropathy in children with nephritic syndrome. Arch Dis Child 2006;91:666–670.